GZ 402666

Drug Profile

GZ 402666

Alternative Names: 2nd generation aglucosidase-alpha; GZ-402666; neo rhGAA; Neo-recombinant human acid alpha-glucosidase; Neo-rhGAA; Neo-rhGAA enzyme therapy; NeoGAA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glycogen storage disease type II

Most Recent Events

  • 10 Jan 2017 Genzyme plans the phase II Mini-COMET trial for Glycogen storage disease type II (In adolescents, In children, In infants, Treatment-experienced) in USA (IV, Infusion) (NCT03019406)
  • 01 Oct 2016 Phase-III clinical trials in Glycogen storage disease type II (In children, In adolescents, In adults, In the elderly) in USA, Belgium, Denmark, France, Netherlands, United Kingdom, Sweden (IV) (NCT02782741)
  • 03 Mar 2016 Efficacy and adverse events data from the phase I/II NEO 1 study in Glycogen storage disease type II released by Sanofi Genzyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top